Analysis
The 2026 IPO market has gone from cautiously reopening to genuinely overheated in the span of about six months, and the data increasingly shows the gap between hype and durable performance widening rather than closing. 203 companies have begun trading on the NYSE or Nasdaq so far this year, but roughly 49% now trade below their offering price -- a near coin-flip outcome that undercuts the market's own celebratory tone around IPO volume.
SpaceX's offering was the year's single defining risk-asset event. Priced at $135 per share, the deal raised $75 billion and briefly pushed shares to nearly $225 in early trading, before a 16% single-session decline erased most of the pop. Shares finished the month near $153 -- still well above the IPO price, but a fraction of the peak enthusiasm that greeted the opening bell.
That trajectory -- explosive first-day pop, partial retracement, then a long grind to figure out fair value -- has effectively become the template for 2026's highest-profile listings, echoing Cerebras's own IPO in May, which priced at $185, opened near $350, and has spent the months since finding a more sustainable trading range. Scribe Therapeutics followed a similar script in late July, pricing at $15 and jumping nearly 67% on its Nasdaq debut.
“Shares finished the month near $153 -- still well above the IPO price, but a fraction of the peak enthusiasm that greeted the opening bell.”
The pattern is not new -- it is, in fact, one of the oldest lessons in public markets: scarcity value during an IPO window, especially one this hyped, routinely produces opening prices disconnected from where a stock eventually settles once lockups expire and ordinary trading volume replaces IPO-week frenzy. What makes 2026 distinctive is the scale and speed at which the window reopened after years of dormancy, and the concentration of the largest deals in AI-adjacent names whose valuations are unusually sensitive to shifts in capex sentiment.
For GPs and LPs evaluating exit timing, the 49% below-water figure is the number that matters more than any single marquee debut: it's a signal that the current IPO window rewards sellers who can time an exit near the opening pop far more reliably than it rewards long-term public shareholders. Anthropic's confidential IPO filing and OpenAI's own path toward a public listing will be the next major tests of whether that pattern holds at even larger scale.
What to watch: whether the percentage of underwater 2026 IPOs improves or worsens as more lockups expire through Q4, how Anthropic's and OpenAI's eventual listings perform relative to the SpaceX and Cerebras templates, and whether underwriters begin pricing new deals more conservatively in response to this year's post-IPO volatility.
